Access to Global Disease Innovation

7 Pages Posted: 16 Nov 2006  

Kevin Outterson

Boston University School of Law

Date Written: November 15, 2006

Abstract

The pharmaceutical IP system works well in high-income countries able to afford government subsidies and social insurance. It does not work for the poor in low and middle-income countries. For global diseases (Types I and II), innovation is assured by high-income country markets alone, permitting an accommodation for the poor in low and medium-income countries such as a patent buyout or other access programs which support equitable access without damaging optimal innovation incentives.

Keywords: intellectual property, IP, access, innovation, essential medicines, patent, pharmaceutical

Suggested Citation

Outterson, Kevin, Access to Global Disease Innovation (November 15, 2006). Available at SSRN: https://ssrn.com/abstract=884241 or http://dx.doi.org/10.2139/ssrn.884241

Kevin Outterson (Contact Author)

Boston University School of Law ( email )

765 Commonwealth Avenue
Boston, MA 02215
United States

Paper statistics

Downloads
162
Rank
149,969
Abstract Views
1,014